Abstract:
The article presents a study results on the dynamics of lipid spectrum under the influence of
combination regimens of lipid-lowering therapy (statin + fibrate and a statin + ω-3 PUFA). The data
shown a significant lipid-lowering effect of combinated therapy by fibrate with a statin on all the
atherogenic fractions. Integrated application of statin with ω-3 PUFA allowed not only to reduce the
atherogenic lipid fractions, but also achieve a higher level of HDL. The results indicate a greater
effectiveness of the medication complex as compared with statin monotherapy, as well as the need for a
differentiated approach to lipid-corrective therapy based on blood lipid fractions baseline.
